Literature DB >> 17934705

[Elderly patients in clinical trials: new fitness-adapted concepts].

V Goede1, M Hallek.   

Abstract

Advanced age is associated with a higher burden of illness. Nevertheless, elderly patients suffering from internal diseases are underrepresented in clinical trials; patient, physician and protocol-designed barriers in particular prevent the recruitment of older patients with impaired medical fitness (co-morbidity, co-medication, poor performance status, cognitive dysfunction etc.). Recommendations that are based on trials in younger subjects mostly cannot be generally adopted for the elderly. Treatment in clinical practice and clinical trials should be fitness-adapted rather than age-adjusted. Normally, standard regimens are effective and well tolerated in medically fit patients of advanced age. In contrast, it may be necessary to apply modified regimens for the medically unfit. Trials exploring novel treatment modalities in the young should always allow the inclusion of elderly patients with good medical fitness. The benefit of modifying a treatment regimen in medically unfit patients of advanced age has to be determined by separate trials.

Entities:  

Mesh:

Year:  2007        PMID: 17934705     DOI: 10.1007/s00108-007-1944-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  Clinical trials in the elderly--a concept comes of age.

Authors:  Lillian L Siu
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

Review 2.  Age and gender bias in statin trials.

Authors:  S Bandyopadhyay; A J Bayer; M S O'Mahony
Journal:  QJM       Date:  2001-03

3.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes.

Authors:  P Y Lee; K P Alexander; B G Hammill; S K Pasquali; E D Peterson
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

4.  Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan.

Authors:  Daniele Bernardi; Isabella Milan; Monica Balzarotti; Michele Spina; Armando Santoro; Umberto Tirelli
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

5.  Representation of patients with dementia in clinical trials of donepezil.

Authors:  Sudeep S Gill; Susan E Bronskill; Muhammad Mamdani; Kathy Sykora; Ping Li; Kenneth I Shulman; Geoffrey M Anderson; Michael P Hillmer; Walter P Wodchis; Paula A Rochon
Journal:  Can J Clin Pharmacol       Date:  2004-12-15

6.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

Review 7.  How to get older people included in clinical studies.

Authors:  Miles D Witham; Marion E T McMurdo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Reporting of age data in clinical trials of arthritis. Deficiencies and solutions.

Authors:  P A Rochon; P R Fortin; K B Dear; K L Minaker; T C Chalmers
Journal:  Arch Intern Med       Date:  1993-01-25

Review 9.  Implantable cardioverter-defibrillators for secondary prevention: is it worth it in the elderly?

Authors:  Darren Traub; Leonard Ganz
Journal:  Am J Geriatr Cardiol       Date:  2006 Mar-Apr

10.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

Authors:  Lilia Talarico; Gang Chen; Richard Pazdur
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  1 in total

1.  Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Authors:  Xavier C Badoux; Michael J Keating; Xuemei Wang; Susan M O'Brien; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Susan Lerner; Hagop Kantarjian; William G Wierda
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.